AI-Powered Innovation: Designing the Next-Gen Degrader Therapeutics

Exhibitor: DEPARTMENT OF SOCIAL WELFARE, TAIPEI CITY GOVERNMENT

Booth No: N402

Characteristic

AnHorn Medicines spearheads protein degradation innovation, pioneering novel therapeutics to tackle previously unaddressed proteins. Powered by AI, our drug discovery platform facilitates the creation of protein degraders, including PROTACs and molecular glues.
AnHorn Medicines' AIMCADD® is a proprietary artificial intelligence-driven drug discovery platform, facilitates the design and optimization of small-molecule inhibitors and degraders, enabling the identification of drug candidates that can selectively target and degrade disease-causing proteins.
The platform's capabilities have been recognized in industry forums, with AnHorn invited to present its AI-driven drug discovery approach at events like the NVIDIA GTC in United States and AI Summit in Taiwan.